Investigator Studies Program (MISP): Respiratory Syncytial Virus (RSV)
Effective September 2018, the Respiratory Syncytial Virus (RSV) Investigator Initiated Studies Program (MISP) Committee will accept proposals within our current areas of interest (AOI) up to January 31, 2019. This is a competitive process that will be conducted by the RSV Vaccine MISP. Decisions will be made on the basis of scientific merit and strategic fit within the AOI. Please review the critical activities and abide by the timelines as outlined below.

The following areas are of interest to Investigator Studies Program Committee:
Infants
  • Translational research studies evaluating immune response to severe RSV disease in infants, including immune responses that may be related to the development of airway hyper-reactivity/recurrent reactive airway disease.
  • Studies that advance the understanding of immune response including correlates of immune protection against RSV infection in infants, including maternal antibody, and passive immunization.
  • Studies in infants to determine risk factors for recurrent wheezing/reactive airway following RSV infection, with attention to age at primary RSV infection and severity of RSV disease.
  • Studies evaluating RSV subgroup-specific (RSV A and RSV B) epidemiology and burden of illness of RSV infection in infants and young children, especially very preterm and late preterm (28-37 weeks gestational age) infants and healthy full term (37+ weeks gestational age) infants in regions, countries or populations in which these data are limited.
  • Studies evaluating the health care resource use and health-economic burden of RSV infection in infants and young children, especially very preterm and late preterm (28-37 weeks gestational age) infants and healthy full term (37+ weeks gestational age) infants in regions, countries or populations in which these data are limited.
  • RSV subgroup-specific (RSV A and RSV B) laboratory surveillance studies in regions, countries or populations in which these data are limited.
Adults
  • Studies evaluating the subgroup-specific (RSV A and RSV B) epidemiology and burden of illness of RSV infection in adults >18 years of age, including pregnant women, adults with underlying cardiopulmonary conditions and older adults (>60 years) in regions, countries or populations in which these data are limited.
  • Studies evaluating the health care resource use and health-economic burden of RSV infection in adults >18 years of age, including pregnant women, adults with underlying cardiopulmonary conditions and older adults (>60 years) in regions, countries or populations in which these data are limited.
  • Studies that advance the understanding of immune response including correlates of immune protection against RSV infection in adults.
  • Studies that advance the understanding of how alterations of an established RSV immune response, including immune senescence, effect of the risk of new RSV acquisition and severity of disease by age and underlying medical conditions.
  • RSV subgroup-specific (RSV A and RSV B) laboratory surveillance studies in regions, countries or populations in which these data are limited.

Please complete a full protocol and detailed budget via Visiontracker, the Company's on-line study management system (in US) or your MSD country representative (outside US). The proposals will be collectively reviewed and selected by the RSV MISP Committee.

Critical Activities and Timelines:

Deadline Dates/Activity Review Cycle
Full Protocol Submission with Detailed Budget January 31, 2019
Final Comments to Investigator March 29, 2019


MISP Information
This site is intended for US investigators only. Investigators outside of the US interested in submitting research proposals to the Investigator Studies Program should contact their local MSD office.